{
    "name": "gadoversetamide",
    "comment": "Rx",
    "other_names": [
        "OptiMARK"
    ],
    "classes": [
        "Gadolinium-Containing Contrast Agents",
        "Contrast Media",
        "Nonionic/ High Osmolality"
    ],
    "source": "https://reference.medscape.com/drug/optimark-gadoversetamide-999603",
    "pregnancy": {
        "common": [
            "GBCAs cross the placenta and result in fetal exposure and gadolinium retention",
            "Human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive",
            "Estimated background risk of major birth defects and miscarriage for the indicated population is unknown",
            "All pregnancies have a background risk of birth defect, loss, or other adverse outcomes"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Estimated infant exposure is 0.001%-0.04% of the maternal dose",
            "Unknown whether the effects of the drug on the breastfed infant or the effects of the drug on milk production",
            "Developmental and health benefits of breastfeeding should be considered together with the mother’s clinical need for the drug and any potential adverse effects on the breastfed infant or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Nephrogenic systemic fibrosis ",
                    "description": [
                        "Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs",
                        "Avoid use of GBCAs in these patients unless diagnostic information is essential and not available with noncontrasted MRI or other modalities",
                        "NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs",
                        "Highest risk for NSF is among patients with chronic, severe kidney disease (GFR <30 mL/min/1.73²) OR acute kidney injury",
                        "Screen patients for acute kidney injury and other conditions that may reduce renal function",
                        "For patients at risk for chronically reduced renal function (eg, age >60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing",
                        "For patients at highest risk for NSF, do not exceed recommended dose and allow a sufficient period of time for elimination of the drug from the body prior to readministration"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, gadoversetamide.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "9.4"
        },
        {
            "name": "Vasodilation",
            "percent": "6.4"
        },
        {
            "name": "Dizziness",
            "percent": "3.7"
        },
        {
            "name": "Nausea",
            "percent": "3.2"
        },
        {
            "name": "Paresthesia",
            "percent": "2.2"
        },
        {
            "name": "Diarrhea",
            "percent": "1.9"
        },
        {
            "name": "Abdominal pain",
            "percent": "1.8"
        },
        {
            "name": "Rhinitis",
            "percent": "2"
        },
        {
            "name": "Injection site reaction",
            "percent": "2"
        },
        {
            "name": "Back pain",
            "percent": "1"
        },
        {
            "name": "Dyspepsia",
            "percent": "1"
        },
        {
            "name": "Seizures",
            "percent": null
        },
        {
            "name": "Amblyopia",
            "percent": null
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Diplopia",
            "percent": null
        },
        {
            "name": "Dry skin",
            "percent": null
        },
        {
            "name": "Dystonia",
            "percent": null
        },
        {
            "name": "Flatulence",
            "percent": null
        },
        {
            "name": "Hyponatremia",
            "percent": null
        },
        {
            "name": "Neck pain",
            "percent": null
        },
        {
            "name": "Pallor",
            "percent": null
        },
        {
            "name": "Parosmia",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Seizure",
            "percent": null
        },
        {
            "name": "Seizures",
            "percent": null
        },
        {
            "name": "Nephrogenic systemic fibrosis",
            "percent": null
        },
        {
            "name": "Hypersensitivity reactions including bronchospasm and laryngeal",
            "percent": null
        },
        {
            "name": "pharyngeal edema",
            "percent": null
        }
    ]
}